BeiGene
BGNE
#881
Rank
HK$172.87 B
Marketcap
HK$1,575
Share price
1.71%
Change (1 day)
4.40%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : HK$18.28 B

According to BeiGene 's latest financial reports the company's total liabilities are HK$18.28 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31HK$17.71 B13.58%
2022-12-31HK$15.59 B-16.77%
2021-12-31HK$18.73 B39.56%
2020-12-31HK$13.42 B171.9%
2019-12-31HK$4.93 B27.12%
2018-12-31HK$3.88 B37.24%
2017-12-31HK$2.83 B589.86%
2016-12-31HK$0.41 B24.71%
2015-12-31HK$0.32 B52.23%
2014-12-31HK$0.21 B-44.84%
2013-12-31HK$0.39 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
HK$94.76 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$4.55 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA